223 related articles for article (PubMed ID: 27155352)
1. Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.
Willemse SB; Jansen L; de Niet A; Sinnige MJ; Takkenberg RB; Verheij J; Kootstra NA; Reesink HW
Antiviral Res; 2016 Jul; 131():148-55. PubMed ID: 27155352
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
[TBL] [Abstract][Full Text] [Related]
4. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
5. Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.
Jansen L; Welkers MRA; van Dort KA; Takkenberg RB; Lopatin U; Zaaijer HL; de Jong MD; Reesink HW; Kootstra NA
Antiviral Res; 2017 Sep; 145():87-95. PubMed ID: 28754258
[TBL] [Abstract][Full Text] [Related]
6. An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B.
Jansen L; de Niet A; Makowska Z; Dill MT; van Dort KA; Terpstra V; Bart Takkenberg R; Janssen HL; Heim MH; Kootstra NA; Reesink HW
Liver Int; 2015 Jul; 35(7):1824-32. PubMed ID: 25533046
[TBL] [Abstract][Full Text] [Related]
7. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
9. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
10. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
Gu J; Sun R; Shen S; Yu Z
Pak J Pharm Sci; 2015 Jul; 28(4 Suppl):1493-7. PubMed ID: 26431662
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.
Sun J; Hou JL; Xie Q; Li XH; Zhang JM; Wang YM; Wang H; Lai JY; Chen SJ; Jia JD; Sheng JF; Chan HL; Wang JF; Li MK; Jiang M; Popescu M; Sung JJ
Aliment Pharmacol Ther; 2011 Aug; 34(4):424-31. PubMed ID: 21692822
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
13. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW
J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898
[TBL] [Abstract][Full Text] [Related]
14. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
Wang YD; Zhao CY; Wang W; Shen C; Lu HZ; Zhang L; Yu WY; Zhou JY; Yan WZ
Hepatogastroenterology; 2012 May; 59(115):680-6. PubMed ID: 22441104
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
Jia W; Zhu MQ; Qi X; Wang T; Wen X; Chen PD; Fan QQ; Zhang WH; Zhang JM
Virol J; 2019 May; 16(1):61. PubMed ID: 31064399
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
18. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
Lu J; Zhang S; Liu Y; Du X; Ren S; Zhang H; Ma L; Chen Y; Chen X; Shen C
Liver Int; 2015 Jun; 35(6):1692-9. PubMed ID: 25438657
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]